How long is Ocaliva’s orphan drug exclusivity?
Ocaliva (obeticholic acid) received orphan drug designation for specific rare liver conditions, which can grant market exclusivity in the US if the drug is approved for the orphan indication. Under the US orphan drug program, that exclusivity is typically 7 years from the date of FDA approval for the orphan indication. The exact start date depends on the approval tied to the orphan indication.
When does Ocaliva’s exclusivity start and what counts as the clock?
The “clock” for orphan exclusivity runs from the FDA approval date for the orphan-designated use. If a drug is later approved for additional indications, those other approvals may have different exclusivity timelines that depend on whether orphan designation applies to those specific indications.
Can Ocaliva lose or shorten orphan exclusivity?
US orphan exclusivity can be reduced or lost in certain circumstances, such as if FDA determines the drug no longer meets orphan criteria (for example, the rare-disease prevalence threshold changes), or if another sponsor demonstrates a clinically superior alternative for the same orphan indication.
Does orphan exclusivity block generic or biosimilar competition by itself?
Orphan drug exclusivity is not the same as patent protection. It can delay approval of certain competitors for the same orphan indication under applicable FDA pathways, but it does not prevent all market entry for every scenario. Patent expiry, patent litigation outcomes, and regulatory eligibility for the same indication all affect when competition actually happens.
How do patents and orphan exclusivity interact for Ocaliva?
Even with orphan exclusivity, competitors may still face:
- Patent barriers (method-of-use, formulation, or composition patents).
- FDA approval constraints tied to indication and labeling.
The practical “earliest competition” date is often determined by the combination of orphan exclusivity (if applicable) plus the last expiring relevant patent(s).
What indication matters most for Ocaliva orphan exclusivity?
Orphan exclusivity depends on the specific orphan-designated indication. For Ocaliva, the exclusivity question is therefore tied to which rare disease label was covered by the orphan designation and which FDA approval date corresponds to that orphan indication.
Are there competing timelines in other countries?
Orphan drug exclusivity rules vary by country (for example, EU orphan market exclusivity follows different criteria and duration rules than the US). The relevant duration and start date depend on the regulator (FDA vs EMA) and the specific orphan program framework.
What information you can check to get the exact Ocaliva date
To pin down the exact “orphan exclusivity expires on” date for Ocaliva, you would normally look up:
- FDA orphan drug designation and the orphan indication.
- The FDA approval date for that orphan indication.
- Any later changes to orphan status or clinically superior determinations.
Sources are required to give the exact date for Ocaliva. If you share whether you mean the US (FDA) or EU (EMA), and which Ocaliva orphan indication you’re targeting, I can format the precise exclusivity expiry date accordingly.